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Abstract: Anovulation is a common cause of female subfertility. Treatment of anovulation 
is aimed at induction of ovulation. In women with clomiphene-citrate resistant WHO 
group II anovulation, one of the treatment options is ovulation induction with exogenous 
follicle-stimulating hormone (FSH or follitropin). FSH is derived from urine or is produced as 
recombinant FSH. Two forms of recombinant FSH are available – follitropin alpha and fol-
litropin beta. To evaluate the efficacy, safety, costs and acceptability of recombinant FSH, we 
performed a review to compare recombinant FSH with urinary-derived FSH products. Follitropin 
alpha, beta and urinary FSH products appeared to be equally effective in terms of pregnancy 
rates. Patient safety was also found to be comparable, as the incidence of side effects including 
multiple pregnancies was similar for all FSH products. In practice follitropin alpha and beta 
may be more convenient to use due to the ease of self-administration, but they are also more 
expensive than the urinary products.
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Introduction
Anovulation is a common cause of infertility in women. It is classified by the World 
Health Organization (WHO) criteria according to endogenous concentrations of serum 
FSH and estradiol. About 80% of anovulatory women have WHO type II or normogo-
nadotrophic normoestrogenic anovulation. Polycystic ovary syndrome (PCOS) is the 
most common form of WHO II anovulatory infertility.
Gonadotropins have successfully been used for ovulation induction in anovulatory 
women. At present there are two classes of FSH-containing pharmaceutical prepara-
tions, those derived from the urine of postmenopausal women and those manufactured 
with recombinant DNA technology.
Gonadotropins are indicated for the induction of ovulation in the anovulatory 
infertile patient and for the development of multiple follicles in the ovulatory patient 
undergoing intra-uterine insemination or participating in an Assisted Reproductive 
Technology program.1
This review aims to evaluate the efficacy, safety and patient acceptability of 
recombinant gonadotropins in ovulation induction in PCOS women. A short history 
of the development of the various FSH products is initially described, followed by 
their pharmacokinetics and isoform profiles. The review then looks into the efficacy, International Journal of Women’s Health 2009:1 206
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safety profiles and patient satisfaction of these products used 
for ovulation induction in comparison with urinary-derived 
gonadotropins.
Short history of gonadotropins 
development
By the late 1950s human pituitary extracts were successfully 
used for ovulation induction in hypogonadotropic women.2 
Since then, human-derived gonadotropin preparations have 
evolved as the mainstay of ovulation induction therapy. 
The use of pituitary extracts was abandoned because of 
scarcity of available human pituitary glands and the fear of 
Creutzveld-Jakob virus.
Pituitary gonadotropins were replaced by urinary derived 
human menopausal gonadotropins by the early 1960s, when 
the first report was published on its use for the treatment of 
ovulatory dysfunction.3
Human menopausal gonadotropins consist of a purified 
preparation of gonadotropins extracted form the urine of 
postmenopausal women. The generic name is menotropins. 
They are inactive orally and are given by intramuscular 
injections. Menotropins were initially only 5% pure, con-
tained equal amounts of luteinizing hormone (LH) and 
FSH and large quantities of potentially allergenic urinary 
proteins.
The next group of gonadotropins to emerge were purified 
FSH preparations or urofollitropins. Urinary FSH contained 
less than 1% LH but was still contaminated with 95% of 
nongonadotrophin-related proteins. In the mid 1990s highly 
purified urinary FSH became available containing less than 
0.1% LH and virtually no urinary proteins, allowing subcuta-
neous administration.2 The production of highly purified FSH 
was enabled by the development and application of produc-
tion techniques based on immuno affinity chromatography 
with monoclonal antibodies.
One cycle of treatment with gonadotropins requires 20 to 
30 L of urine from postmenopausal women.4 The increased 
demand for gonadotropins and the advances in molecular 
technology lead to the production of recombinant FSH. 
This was also driven by the fear of infections, for example 
Creutzveld-Jakob virus, although no infectivity from the 
urine of humans has ever been detected in four decades of 
use.5–7 However, recombinant follitropins are produced from 
a hamster cell line and this procedure also bears a theoretical 
risk of introducing viruses into humans, although again this 
has never been described.8
By transfecting a Chinese hamster ovary cell line with 
FSH genes recombinant FSH could be stably produced and 
was introduced in clinical practice in 1992.9 Recombinant 
FSH is homogenous and free of contamination by proteins. 
Two recombinant preparations are available – follitropin 
alpha (Gonal F®; Serono Labarotories, Switzerland) and 
follitropin Beta (Puregon®; Schering-Plough Laboratories, 
the Netherlands).
FSH: pharmacokinetics 
and isoforms
FSH is a glycosylated hormone and is composed of two 
noncovalently linked polypeptide chains, an alpha and a beta 
subunit. In this heterodimeric structure the alpha and beta 
subunits confer its biological and immunological activity. 
The alpha unit is similar to other pituitary and placenta 
hormones (LH, thyroid-stimulating hormone [TSH] and 
human chorionic gonadotropin [hCG]). The oligosaccharides 
in the beta subunit of FSH are highly variable and the compo-
sition and complexity of the attached carbohydrate moieties 
may differ. Each oligosaccharide may show single branched, 
di- tri- and even tetrabranched structures.10 Each branch of 
the oligosaccharides determines the terminal sialylation 
of the negatively charged FSH molecule and so a number 
of isoforms exist. In humans 20 different FSH isoforms have 
been identified. The liver metabolism of FSH isoforms with 
a high number of sialic acid residues (ie, acidic isoforms) is 
considerably lower compared to isoforms with a low con-
tent of sialic acid residues (ie, less acidic isoforms). As a 
consequence, the plasma half-life of the most acidic isoforms 
is about 240 minutes, while the least acidic isoforms have a 
plasma half-life of about 180 minutes.11,12
The terminal sialylation of human FSH determines the 
overall charge of the molecule. The iso-electric point can 
range from 3.5 to 7.0.13 The recombinant FSH products dif-
fer from the urinary products in that they contain less acidic 
FSH isoforms. Slightly different purification processes 
affect the carbohydrate compositions.14 The isoform profile 
of both recombinant preparations are similar, although fol-
litropin alpha is less acidic due to the larger extent of basic 
isoforms (isoform ranges [4–5] compared with follitropin 
beta [isoform ranges 3.5–5.5]).
Ovulation induction
An indication for the use of gonadotropins is anovulation not 
responding to clomiphene citrate. There are three classes of 
anovulation, ie, WHO I, WHO II and WHO III.15–17 Women 
with WHO class I anovulation, which accounts for 10% of 
anovulatory women, have low or low–normal serum FSH 
concentrations and low serum estradiol concentrations due to International Journal of Women’s Health 2009:1 207
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decreased hypothalamic secretion of gonadotropin-releasing 
hormone (GnRH) or pituitary unresponsiveness to GnRH. 
The causes of hypothalamic amenorrhea include stress- or 
exercise-related amenorrhea, anorexia nervosa and Kallmann 
syndrome.
The majority of women with WHO type I anovulation do 
not have the threshold levels of endogenous LH required to 
achieve optimal follicular development and steroidogenesis 
during therapy with FSH alone.17,18 Most important is that 
no term pregnancy occurred with this treatment. In these 
women an exogenous supply of LH is required to achieve 
an adequate follicular response. At present women with 
hypogonadotropic anovulation are most commonly being 
treated with human menopausal gonadotropin (hMG) or, 
mostly in a trial context, with a combination of recombinant 
FSH (rFSH) and LH.
About 80% of the women that suffer from infertility 
due to anovulation have WHO class II anovulation. The 
majority of these women have polycystic ovary syndrome 
(PCOS). The most recently developed criteria for PCOS 
require the presence of at least two of the following three 
criteria: oligo- and or anovulation, hyperandrogenism 
(clinical or biochemical) and ultrasonic appearance of poly-
cystic ovaria.19 The conventional treatment of WHO class II 
anovulatory women is clomiphene citrate with or without 
metformin, which will restore ovulation in almost 80% of 
women and will result in pregnancy in 50% of all women. In 
women with clomiphene resistance and clomiphene failure, 
gonadotropins are the next line of treatment.
Ovulation induction in women 
with PCOS
Ovulation induction with gonadotropins carries a risk for 
multiple follicular development and multiple pregnancies. 
A chronic low-dose step-up regimen was introduced to 
reduce the incidence of these complications. Following 
spontaneous or progesterone induced bleeding, a course of 
37.5 IU to 75 IU of daily FSH treatment is commenced on 
day 3 of the cycle until ovulation is induced. This starting 
dose is continued for 14 days. Ovarian response is monitored 
by transvaginal ultrasound and incremental FSH doses are 
given until an adequate response has been achieved. If a 
dominant follicle emerges, the dose of FSH is maintained 
until the follicle reaches a main diameter of 17 mm or above. 
At this point HCG is injected. With more than 3 dominant 
follicles the cycle is cancelled. The low-dose step-up pro-
tocol has a clinical pregnancy rate of about 20% per cycle, 
an incidence of ovarian hyperstimulation syndrome (OHSS) 
of 1% to 3% and a multiple pregnancy rate ranging from 
10% to 25%.20–23
Efficacy, safety and cost of ovulation 
induction with recombinant FSH; 
a literature search
In a Cochrane library meta-analysis from 2001, the efficacy 
of urinary FSH (uFSH) and rFSH for induction of ovulation 
was compared in clomiphene resistant anovulatory women.24 
Three randomized controlled trials were included. Two trials 
compared follitropin alpha with highly purified uFSH (HP 
uFSH)25,26 and the third trial compared follitropin beta with 
HP uFSH.27 No significant differences were found between 
the two treatment groups in ovulation rate, pregnancy rate, 
miscarriage, multiple pregnancy rate. The review concluded 
that there was no evidence of a difference between both 
rFSH and HP uFSH for ovulation induction in women with 
PCOS.
We searched the literature for more recent data. A trial 
was included if it dealt with the use of follitropin alpha versus 
follitropin beta or recombinant gonadotropins versus urinary 
gonadotropins. To identify all relevant trials we searched the 
Embase (1966 to November 2008) and Medline databases 
(1988–November 2008).
All randomized controlled trials which included patients 
with primary or secondary infertility attributed to an ovula-
tion disorder were included in this review.
Unfortunately most studies did not differentiate between 
women with clomiphene resistance and clomiphene failure, 
which is why we included both categories in our review.
We considered the following outcome measures after the 
first treatment cycle:
1.  Pregnancy outcomes and ovulation: live birth rate per 
woman, ongoing pregnancy rate per woman, clinical 
pregnancy rate per woman and ovulation rate per cycle.
2.  Unintended effects: OHSS per cycle, multiple pregnancy 
rate per woman and local and systemic side effects per 
woman.
3.  Cost-related effects: total dose of gonadotropins admin-
istered, duration of gonadotropin treatment.
We identified 9 relevant randomized controlled trials that 
compared recombinant FSH with urinary gonadotropins.25–33 
One trial was excluded as it studied differential effects on 
hemostasis.32 A further 2 trials were excluded as pregnancy 
results after 1 treatment cycle could not be extracted.29,33 Two 
trials reported the data of 3 treatment cycles, without reporting 
the results of the first treatment cycle.29,33International Journal of Women’s Health 2009:1 208
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A detailed description of the 6 trials included in this 
review is given in Table 1. Four trials compared follitropin 
alpha with HP urofollitropin.25,26,28,31 One trial compared 
follitropin alpha with highly purified HMG30 and 1 trial com-
pared follitropin beta with HP urofollitropin.27 The starting 
dose in these trials varied between 37 and 75 IU per day.
When at least 2 trials studied a similar comparison, data 
were pooled and a summary statistic was calculated using 
a fixed-effects model. For dichotomous data a pooled (odds 
ration, OR) with 95% confidence interval (CI) was calculated 
using the Peto method. For continuous data the mean differ-
ences were pooled and a mean weighted difference with 95% 
CI was calculated. Review Manager Software (RevMan 5, 
Cochrane Collaboration, Oxford, UK) was used for statisti-
cal analysis.
Pregnancy outcomes and ovulation
All dichotomous outcomes for the trials comparing recom-
binant gonadotropins and urinary gonadotropins are sum-
marized in Figure 1. None of the included 6 trials found 
a significant difference for any of the reported pregnancy 
outcomes.
Four trials reported data on live birth rate per women after 
the first treatment cycle. Pooling the data resulted in an OR 
of 1.12 (95% CI 0.75–1.66) for recombinant gonadotropins 
versus urinary gonadotropins.25,28,30,31
Ongoing pregnancy rate data were reported in 3 
trials.27,28,30 Pooling the ongoing pregnancy rate data of the 
3 trials resulted in an OR of 1.27 (95% CI 0.78–2.07).
Clinical pregnancy rate data were reported in 3 trials.26,28,30 
Pooling the clinical pregnancy data of these trials resulted in 
an OR of 1.13 (95% CI 0.67–1.89).
All 6 trials reported data on ovulation rate. Pooling these 
data resulted in a significantly higher ovulation rate after 
rFSH in comparison to urinary gonadotrophins (OR 1.40; 
95% CI 1.03–1.92).25–28,30,31 Hence, significantly more 
women were ovulatory after the use of recombinant FSH 
when compared with urinary preparation, but this did not 
lead to a higher pregnancy rate. There was no indication 
for statistical heterogeneity between the trials for any of 
these outcomes.
Unintended effects
Since the implementation of the low-dose step-up regimen 
and the introduction of OHSS management protocols, the 
major complication of ovarian stimulation is multiple preg-
nancies. Due to adherence to the cancellation criteria the 
incidence OHSS is generally low. In the trials OHSS rates 
Table 1 Characteristics of the six included trials
References Comparison Population
Balen28 Follitropin alpha vs  
HP FSH (Bravelle®)
Infertile women with WHO group II anovulation, resistant to CC, with 
CC resistance defined as a failure to ovulate with CC of at least  
100 mg/day for 5 days or failed to conceive after three ovulatory  
cycles (N = 151, cycles 151). Only the first cycle was included
revelli31 Follitropin alpha vs  
HP FSH (Metrodin®)
Infertile women with WHO group II anovulation, resistant to CC, with 
CC resistance defined as a failure to ovulate with incremental doses 
of CC up to 200 mg/day for 5 days in 3 treatment cycles (N = 76, 
cycles 76) and normo-ovulatory patients with unexplained subfertility 
(N = 184, 184 cycles). Only the first cycle in included
Platteau30 Follitropin alpha vs  
HP HMG (Menopur®)
Infertile women with WHO group II anovulation, resistant to CC,  
with CC resistance defined as a failure to ovulate with CC of at least 
100 mg/day for 5 days or failed to conceive after three ovulatory 
cycles (N = 184, cycles 184). Only the first cycle was included
Yarali26 Follitropin alpha vs  
HP FSH (Metrodin®)
Infertile women with WHO group II anovulation, resistant to CC, with 
resistance defined as a failure to ovulate with incremental doses of CC 
up to 150 mg/day for 5 days or failure to conceive with the ovulatory 
doses of CC during 6 ovulatory cycles (N = 51, 96 cycles).   The first 
3 cycles were included
Coelingh Bennink27 Follitropin beta vs  
HP FSH (Metrodin®)
Infertile women with WHO group II anovulation, resistant to CC, 
defined as a failure to ovulate during 3 previous medication cycles or 
to conceive during 6 ovulatory cycles. (N = 178 patients, 361 cycles). 
The first 3 cycles were included
Loumaye25 Follitropin alpha vs  
HP FSH (Metrodin®)
Infertile women with WHO group II anovulation, resistant to CC  
(N = 222)
Abbreviations: CC, clomiphene-citrate; HP FSH, highly purified follicle-stimulating hormone; HP hMG, highly purified human menopausal gonadotropin.International Journal of Women’s Health 2009:1 209
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ranged from zero to 3.2% per treatment cycle. Most were 
mild or moderate OHSS, with only one severe OHSS in the 
whole group of 856 women.
All  six  randomized  trials  reported  on  multiple 
pregnancies.25,28,30,31 Multiple pregnancies occurred in 14 of 
the 443 women in the recombinant FSH group and in 21 of 
419 women in the urinary gonadotropin group (odds ratio 
0.68; 95% CI 0.34–1.36). Most studies reported pregnancy 
rates after three treatment cycles. Only three trials reported 
the multiple pregnancy rate after the first treatment cycle.28,30,31 
Pooling these data also did not reveal significant differences 
(OR 2.54; 95% CI 0.58–11.13) (Figure 1).
Local side effects were reported by 5 trials. Bruising, 
erythema, pain and itching are some of the most commonly 
reported reactions around the injection site. There were 
no indications for differences between recombinant or 
urinary gonadotrophin preparations. However, there were 
large differences in incidence of the different local reac-
tions between trials ranging from 0% up to 50%.25,28,30,31,33 
These large differences between trials were also seen for 
systemic side effect incidences. The most common systemic 
side effects were pelvic pain, nausea or headache and the 
incidences ranged between trials from 0% to 40%.25–28,30,31
Numerous studies have investigated the impact of fertility 
treatments on cancer risk in the general population. There 
is no evidence for an increase in cancer risk with exposure 
to fertility medication.34,35 Furthermore, the use of gonado-
tropins to induce ovulation does not appear to affect future 
fecundity.
Economic evaluation of ovulation 
induction with follitropin alpha
Besides effectiveness and safety, costs play an important role 
in deciding which treatment to give to a patient. The relative 
cost per gonadotropin preparation increases with its purity, 
but the absolute costs differ between countries.
The cost and effects of follitropin alpha and beta were 
compared with HP uFSH in 2 randomized controlled 
trials.29,31 The trial comparing follitropin alpha with HP uFSH 
revealed a significantly lower requirement of FSH when 
using follitropin alpha (Gonal-F), with mean doses of 844 IU 
and 668 IU per cycle respectively.29 The total costs however 
were higher for follitropin alpha though this difference was 
not statistically significant (mean cost per cycle of €208 for 
Gonal F versus €175 for HP uFSH).
The other trial, comparing follitropin beta and HP 
uFSH, also found a significantly lower requirement of FSH 
when using follitropin beta (Puregon) though there was no 
indication for a difference in duration of stimulation (mean 
10.2 days versus 9.8 days).31 The total costs per cycle however 
were significantly higher for a follitropin beta cycle due to 
the lower costs per IU of HP uFSH. (mean cost per cycles for 
follitropin beta was €312 versus €218 for HP FSH).
Five trials compared duration of treatment and all six 
trials compared total the total gonadotrophin dose used. 
We observed a significantly shorter duration of treatment 
with rFSH compared with uFSH (weighted mean difference 
[WMD] minus 1.76; 95% CI -2.59 to -0.93).26–28,30,31 Also 
weighted means for the total FSH dose were lower during 
treatment with rFSH (WMD -242; 95% CI -338 to -146).
Patient acceptability
It is important for patients to choose the product that meets 
their needs.36 Gonadotropins are injected daily for several 
days in follicular phase and various injection or reconstitution 
devices are available to facilitate self-injection.
Historically, human derived gonadotropin prepara-
tions were administered by intramuscular injections (im). 
Figure 1 The studies’ pooled odds ratios (Or) for pregnancy outcomes and ovulation rate.
Abbreviations: rFSH, recombinant follicle-stimulating hormone; uFSH, urinary follicle-stimulating hormone.
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The introduction of highly purified forms of uFSH and rFSH 
enabled subcutaneous injection which is less painful than im 
administration.
In several studies the follitropin alpha and follitropin beta 
injection pen was compared to a conventional device. A pen 
was easier to use, more convenient and less painful compared 
to conventional syringe and vials.36–38
Patient and nurse satisfaction of follitropin alpha com-
pared to beta were assessed in 2 randomized controlled trials. 
In a pilot study among 31 patients, most women favored 
the follitropin alpha pen over the earlier-used follitropin 
beta pen because preparation was faster; they were more 
confident of accurate dosing and had to make fewer dose 
adjustments. Comparable results were found in another trial 
among 140 women and nurses.39
Discussion
In this review we evaluated the efficacy, side effects, costs 
and patient acceptability of follitropin alpha and beta in ovu-
lation induction in mainly WHO class II anovulatory women. 
On basis of the current best available evidence we found no 
differences in pregnancy and safety outcomes between the 
recombinant forms of FSH and urinary gonadotropins.
Both recombinant and urinary preparations are acceptable 
for patients. There are no indications that patients prefer one 
preparation over the other. The patient acceptability appears 
to be mainly influenced by the mode of administration.
The advantage of recombinant FSH over the urinary-
derived FSH products is that small doses can easily be applied 
without having to use half ampoules. Furthermore there are 
no problems with its availability, while large quantities of 
urine from menopausal women are required for urofollitropin 
production.
The bioactivity and glycoform profile is of interest when 
comparing cost effectiveness. The more basic rFSH would 
have a higher biopotency, but this is beneficial only when 
it translates into lower doses of gonadotropins used and 
a shorter duration of stimulation leading to lower costs. 
Indeed, we showed in this review that the use of recombi-
nant gonadotropins leads to a lower dosage requirement 
and a slightly shorter stimulation period. On the other 
hand, rFSH is more expensive than urinary-derived FSH 
products. The costs per cycle of r FSH and HP FSH were 
compared in 2 trials and in both the cost per cycle were 
higher for rFSH even though in both trials a lower FSH 
dose could be used.31
When comparing the effectiveness of rFSH and uFSH the 
differences between women with clomiphene resistance and 
clomiphene failure are of interest. These women probably have 
different fertility prospects. An individual patient data meta-
analysis would be needed to differentiate between women with 
clomiphene resistance and clomiphene failure.
In conclusion there were no indications of a difference 
in effectiveness, safety and tolerability between recombinant 
and urinary follitropins. Follitropin alpha and beta may be 
more convenient to use due to the ease of self-administration, 
but they are also more expensive than the urinary products. 
Any choice the clinician makes on what gonadotropin to use 
for ovulation induction is a good one.
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